Meeting
2016 ASCO Annual Meeting
Prospective multicenter study of the impact of the Prosigna assay on adjuvant clinical decision-making in women with early stage breast cancer: which patients are the best candidates?
Authors
Roman Rouzier
Insitut Curie, Paris, France
Roman Rouzier , David Gentien , Jean Marc Guinebretiere , Marie-Ange Mouret-Reynier , Coraline Dubot , Paul H. Cottu , Cyrille Huchon , Sonia Zilberman , Helene Berseneff , Cyril Foa , Remy Salmon , Myriam Delomenie , Diane De Croze , Aurelie Roulot , Amandine Bonhomme , Anne Vincent- Salomon , Anne Cayre , Celine Callens , Frederique Madeleine Penault-Llorca , Delphine Hequet
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT02395575
Citation
J Clin Oncol 34, 2016 (suppl; abstr 543)
DOI
10.1200/JCO.2016.34.15_suppl.543
Abstract #
543
Poster Bd #
31
Abstract Disclosures
Similar Posters
First Author: Emily Oldham Jenkins
Poster
2023 ASCO Annual Meeting
Gene expression profiling of paired primary breast cancers and brain metastases to identify brain metastases-specific biological changes.
First Author: Gaia Griguolo
Poster
2022 ASCO Annual Meeting
Identification of transcriptional changes with MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant chemotherapy.
First Author: Alice P. Chung
Poster
2019 ASCO Annual Meeting
PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.
First Author: Pier Franco Conte